Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Pfizer’s Biosimilar Strategy Might Be Working

10 hours 39 min ago

Pfizer's biosimilar franchise  is well on its way to becoming a blockbuster business three years after the company launched its...

      Related Stories 

Surprise! Pfizer And Lilly File Tanezumab For Pain With FDA Despite Safety Questions

10 hours 50 min ago

The partners have filed the first-in-class NGF inhibitor at the lower 2.5mg dose for the treatment of osteoarthritis pain, despite...

      Related Stories 

Acceleron Buoyed By Sotatercept’s Promise In PAH

16 hours 16 min ago

Top-line Phase II results from the PULSAR study suggest Acceleron’s sotatercept is effective as add-on treatment for patients with PAH...

      Related Stories 

AZ Gets IBD Drug Back From Allergan

Mon, 01/27/2020 - 11:42pm

Allergan is selling its Crohn’s disease and ulcerative colitis drug brazikumab back to AstraZeneca to satisfy regulators ahead of its...

      Related Stories 

Hilleman CEO Moving On, Hands Baton To Ex-Takeda Executive

Mon, 01/27/2020 - 11:37pm

Hilleman CEO Davinder Gill is leaving the global vaccine R&D organization after eight years at the helm and several mileposts...

      Related Stories 

Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?

Mon, 01/27/2020 - 6:46pm

While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in...

      Related Stories 

The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

Mon, 01/27/2020 - 11:52am

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts...

      Related Stories 

Novartis Pharma President Marie-France Tschudin On Inclisiran, Launches And More

Mon, 01/27/2020 - 10:22am

Tschudin talked to Scrip about taking over as Novartis Pharmaceuticals president, why inclisiran is different from marketed PCSK9 inhibitors and...

       

AZ Closer To Second Enhertu OK After Gastric Cancer Success

Mon, 01/27/2020 - 7:37am

The Daiichi Sankyo-partnered antibody drug conjugate has just been approved for breast cancer and AstraZeneca's oncology R&D chief tells Scrip...

      Related Stories 

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

Mon, 01/27/2020 - 4:55am

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors...

      Related Stories 

Moderna, Inovio Coronavirus Vaccine Candidates Fast-Tracked By International Coalition

Mon, 01/27/2020 - 12:19am

The Coalition for Epidemic Preparedness Innovations adds new deal with mRNA specialist Moderna for rapid development of coronavirus vaccine.

      Related Stories 

Rising Costs, Price Pressure Usher In Uncertain Year Of The Rat In China

Sun, 01/26/2020 - 8:59pm

Once the world's factory, China has seen costs inch up while drug prices are being cut deeply by centralized procurement...

      Related Stories 

Biocon-Mylan's Plans For Broader US Fulphila Access, Glargine On Track

Sun, 01/26/2020 - 8:17pm

Biocon-Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the...

      Related Stories 

JT Gains World-First Topical JAK Inhibitor Approval

Sun, 01/26/2020 - 7:45pm

Latest new drug approvals in Japan include the first anywhere for a topical JAK inhibitor and also a marketing clearance...

      Related Stories 

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Fri, 01/24/2020 - 12:21pm

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger...

      Related Stories 

Pages